[Adjuvant chemotherapy in primary radically operated ovarian cancer]

There are no conclusive studies on the value of adjuvant chemotherapy in radical resected ovarian carcinoma. General reflections including parameters, toxicity and formation of a secondary tumor suggest forgoing adjuvant therapy of stages Ia to IIa. The survival rate of all other stages is below 50%. A therapy would seem necessary. Only general recommendations can be made due to lack of conclusive trials.